妇科恶性肿瘤患者CD3AK细胞与LAK细胞体外增殖能力动态观察

被引：5

作者：

王建六

刘俊英

阳豫

杨茹镜

封全灵

机构：

[1] 河南医科大学第三附属医院妇产科!郑州,,河南医科大学第三附属医院妇产科!郑州,,河南医科大学第三附属医院妇产科!郑州,,河南医科大学第三附属医院妇产科!郑州,,河南医科大学第三附属医院妇产科!郑州,

来源：

河南医科大学学报 | 1998年 / 01期

关键词：

妇科恶性肿瘤; CD3AK细胞; LAK细胞; 增殖;

D O I：

10.13705/j.issn.1671-6825.1998.01.001

中图分类号：

R737.3 [女性生殖器肿瘤];

学科分类号：

100214 ;

摘要：

采用CD3MAb＋IL－2联合刺激法制备了妇科恶性肿瘤患者CD3AK细胞，体外动态观察CD3AK细胞的形态特征及增殖能力，井与LAK细胞进行比较。结果显示：①CD3AK细胞与LAK细胞在体外分别经CD3MAb（0．5mg／L）＋IL－2（105U／L）和IL－2（106U／L）刺激后，细胞体积增大，继之变为不规则形；②CD3AK细胞培养第1周增殖倍数为2．89，至第4周增殖倍数达109．37倍，均显著高于同期培养的LAK细胞的增殖倍数；③CD3AK细胞体外存活时间为4～5周，而LAK细胞仅为2～3周。结果提示：CD3AK细胞制备简便，体外存活时间长，增殖能力强，可以为临床提供充足的过继免疫效应细胞。

引用

页码：1 / 4

页数：4

共 7 条

[1]

OKT3:a monoclonal anti-human T lymphocytes antibody with potant mitogenic properties. Wanwe JV,Mey JR,Goossers JG. J Immunol . 1980

[2]

Arandomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Ratoo GB,Zino P,Mirabelli S,et al. Cancer . 1996

[3]

Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus inteleu-kin-2,identification and isolation of effector subsets. Ochoa AC,Hasz DE,Rezonew R,et al. Cancer Research . 1989

[4]

Observation on the systemic administration of autologus lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. Rosenberg SA,Lotze MT,Muul LM,et al. The New England Journal of Medicine . 1988

[5]

Treatment of cancer patients with ex-vivo anti-CD3-activated killer cells and interleukin-2. Curi BD,Longo DL,Ocnoa AC,et al. Journal of Clinical Oncology . 1993

[6]

The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity. Watanabe H,Narumi K,Stewart CC,et al. Anticancer Research . 1992

[7]

Regional administration of lymphokine-activated killer cells can be superior to intravenous application. Keilholz V,Schlag P,Tilgen W,et al. Cancer . 1992

← 1 →